2024-07-19 17:01:43 ET
Summary
- A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial initiation is expected in Q1 2025.
- Results from the phase 2 SPECTRA study, using the same gene therapy 4D-150 for the treatment of patients with diabetic macular edema, expected in Q4 of 2024.
- The global diabetic macular edema market is expected to reach $3.93 billion by 2029.
- 1E15 vg dose of 4D-710 cleared for dose expansion portion of phase 2 AEROW study; Updated interim data expected in mid-2025.
The last time I wrote about 4D Molecular Therapeutics, Inc. ( FDMT ), it was in a Seeking Alpha article entitled “ 4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024. ” In this article, I really discussed the potential of using its 4D-710 gene therapy for the treatment of patients with Cystic Fibrosis [CF] who are ineligible to receive CFTR modular therapy in its ongoing phase 1/2 study. A good reason to go over this biotech again is because not only was it able to report positive interim data from this specific trial, but has also selected 1E15 vg dose level as its phase 2 expansion dose. This brings about two catalysts as it relates to this program....
Read the full article on Seeking Alpha
For further details see:
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data